Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 5, 2010, Pages 459-468

  Connelly, Margery A ^a   Parry, Tom J ^a   Giardino, Edward C ^a   Huang, Zhihong ^a   Cheung, Wai Man ^a   Chen, Cailin ^a   Cools, Frank ^a   Van Der Linde, Henk ^a   Gallacher, David J ^a   Kuo, Gee Hong ^a   Sarich, Troy C ^a   Demarest, Keith T ^a   Damiano, Bruce P ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

CETP; Cholesteryl ester transfer protein; Endothelial function; Torcetrapib; Ultrasound imaging

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; JNJ 28545595; JNJ 28614872; NITROPRUSSIDE SODIUM; NORADRENALIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; EAR ARTERY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; QUINOLINES; RABBITS; VASODILATION;

EID: 77952992021     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181cf03cb     Document Type: Article

References (31)

1. Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
2. Tall A. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255-1274.
3. Cho K-H, Shin YW, Choi M-S, et al. In vivo effects of CETP inhibitory peptides in hypercholesterolemic rabbit and cholesteryl ester transfer protein-transgenic mice. J Biochem Mol Biol. 2002;35:172-177.
4. Morehouse LA, Sugarman ED, Bourassa P-A, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48:1263-1272.
5. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036.
6. Whitlock ME, Swenson TL, Ramakrishnan R, et al. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest. 1989;84:129-137.
7. Zhang B, Fan P, Shimoji E, et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing highdensity lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol. 2004;24:1910-1915.
8. Zuckerman S, Evans G. Cholesteryl ester transfer protein inhibition in hypercholesterolemic hamsters: kinetics of apoprotein changes. Lipids. 1995;30:307-311.
9. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
10. Bots ML, Visseren FL, Evans GW, et al; Radiance Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study) : a randomised, double-blind trial. Lancet. 2007;370:153-160.
11. Kastelein JJP, van Leuven SI, Burgess L, et al; Radiance Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
12. Barter PJ, Caulfield M, Eriksson M, et al; Illuminate Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
13. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-1473.
14. Kuo G-H, Rano T, Pelton P, et al. Design, synthesis and biological evaluation of (2 R, aS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy) phenyl]-5-[3-(trifluoromethoxy)-phenyl]-a-(trifluoromethyl)-1-(2H) -quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor. J Med Chem. 2009;56:1768-1772.
15. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation). Circulation. 2008;118:2506-2514.
16. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118:2515-2522.
17. Bloch MJ, Basile J. Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone. J Clin Hypertens. 2008;10:160-163.
18. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004; 109: II27-II33.
19. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation. 2004;110:1926-1932.
20. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation. 2005;111:70-75.
21. Bugiardini R, Manfrini O, Pizzi C, et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004;109:2518-2523.
22. DePasquale M, Cadelina G, Knight D, et al. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors. Drug Dev Res. 2009;70:35-48.
23. Stroes E, Kastelein J, Bernardeau A, et al. Absence of effect of R1658/JTT-705 on blood pressure and tissue expression of renin-angiotensin system-related genes in rats. J Am Coll Cardiol. 2008; 51: A322. Abstract.
24. Capponi A, Clerc R, Campos L, et al. No increase in the in vitro production of aldosterone or the expression of CYP11B2 with the CETP modulator dalcetrapib (RO4607381/JTT-705), in contrast to torcetrapib. Circulation. 2008; 118: S452. Abstract.
25. Cachofeiro V, Miana M, de Las Heras N, et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol. 2008;109:331-335.
26. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol. 2009;157:527-536.
27. Hermann F, Enseleit F, Spieker LE, et al. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb Res. 2009;123:460-465.
28. Iiyama K, Nagano M, Yo Y, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J. 1996;132:779-782.
29. Schmidt HH, Walter U. NO at work. Cell. 1994;78:919-925.
30. Nejatizadeh A, Kumar R, Stobdan T, et al. Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. Free Radic Biol Med. 2008;44:1912-1918.
31. Balakumar P, Kaur T, Singh M. Potential target sites to modulate vascular endothelial dysfunction: current perspectives and future directions. Toxicology. 2008;245:49-64.